{"entity":{"id":"in-vitro-transcription","kind":"term","name":"In vitro transcription for RNA products","aka":["IVT RNA production","in-vitro-transcribed RNA"],"tldr":"Enzymes can copy a DNA template into RNA outside a living cell. Producing the transcript is followed by questions about its identity, composition and suitability for use.","summary":"Experimental RNA-manufacturing studies distinguish the intended in vitro-transcribed RNA from contaminating products and test how purification affects its performance. A primary RNA-construct study then measured expression and immune stimulation after delivering transcripts to cells. RNA production, product quality and biological performance are separate observations. An RNA yield or a band of the expected size alone does not establish a released product or a clinical treatment effect.\n\nA protocol from authors affiliated with TriLink Biotechnologies describes co-transcriptional capping with the company's CleanCap AG reagent, reported to give 94 per cent cap 1 structure at 5 mg/ml of transcription, against cap 0 products at lower efficiency from first-generation cap analogues (Henderson and colleagues). It describes one reagent and is not a release specification. Separately, T7 polymerase initiated transcription from a promoter-less DNA end and made an antisense strand that paired with the intended RNA as long double-stranded RNA, which stimulated the innate sensor MDA5; the activity was suppressed by modified nucleotides or a lower magnesium concentration (Mu and colleagues). Release analytics are layered: reviews list sequence and modification identity, poly(A) tail, RNA content by UV spectrophotometry, integrity and transcript length by gel or capillary electrophoresis or chromatography, double-stranded RNA by immunoblot or ELISA, and residual DNA as separate attributes; purification has to remove template DNA, unincorporated nucleotides and enzymes; residual nucleotides are controlled below predefined thresholds that need much lower detection limits than the main product, with the intact mRNA itself complicating their detection (Losada and colleagues; Nowak and colleagues). Because RNA content and integrity are separate assays, total mass alone does not show full-length product.","asOf":"2026-11-09","links":[{"label":"Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA.","url":"https://doi.org/10.1093/nar/gkr695"},{"label":"A Facile Method for the Removal of dsRNA Contaminant from In Vitro-Transcribed mRNA.","url":"https://doi.org/10.1016/j.omtn.2019.02.018"},{"label":"Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells.","url":"https://doi.org/10.1182/blood-2006-04-015024"},{"label":"Cap 1 Messenger RNA Synthesis with Co-transcriptional CleanCap® Analog by In Vitro Transcription.","url":"https://doi.org/10.1002/cpz1.39"},{"label":"An origin of the immunogenicity of in vitro transcribed RNA.","url":"https://doi.org/10.1093/nar/gky177"},{"label":"From nucleotides to intact transcripts through oligonucleotides: Integrated chromatographic strategies for therapeutic mRNA characterization.","url":"https://doi.org/10.1007/s00216-026-06615-x"},{"label":"Process and analytical strategies for the safe production of mRNA vaccines and therapeutics.","url":"https://doi.org/10.1007/s11033-026-11455-0"},{"label":"NEB: Evaluation of IVT Reaction Products, analytical protocol","url":"https://www.neb.com/en-us/protocols/evaluation-of-ivt-reaction-products?pdf=true"}],"tags":[],"related":["mrna-construct-anatomy","dsrna-impurities","chemistry-manufacturing-controls","plasmid-dna-manufacturing"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["In vitro transcription copies a DNA template into RNA outside living cells. A T7 promoter recruits the transcription machinery; a Kozak context acts at translation initiation. Cap addition during transcription or afterwards, and template-encoded or enzyme-added poly(A), are distinct process choices. The DNA is a manufacturing input; residual DNA in the product is a separate quality attribute. Preserve the connection from the intended antigen sequence through the finished construct and its expression and potency tests.","NEB's IVT evaluation protocol says unincorporated nucleotides and template DNA affect the 260-nanometre absorbance reading and calls for their removal before RNA quantification. This is vendor analytical guidance, not a clinical specification. Record purification and the quantification method separately from transcript length and integrity; total mass alone does not identify full-length RNA."],"category":"Methods and models"},"route":"/terms/in-vitro-transcription/","neighbours":{"term":[{"id":"chemistry-manufacturing-controls","kind":"term","name":"Chemistry, manufacturing and controls","route":"/terms/chemistry-manufacturing-controls/"},{"id":"codon-optimization","kind":"term","name":"Codon optimization","route":"/terms/codon-optimization/"},{"id":"dsrna-impurities","kind":"term","name":"Double-stranded RNA impurities","route":"/terms/dsrna-impurities/"},{"id":"immune-product-evidence","kind":"term","name":"Immune measurements and product evidence","route":"/terms/immune-product-evidence/"},{"id":"mrna-construct-anatomy","kind":"term","name":"Messenger RNA construct anatomy","route":"/terms/mrna-construct-anatomy/"}],"technology":[{"id":"plasmid-dna-manufacturing","kind":"technology","name":"Plasmid DNA and mRNA raw-material manufacturing","route":"/technologies/plasmid-dna-manufacturing/"}]}}